GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Humacyte Inc.
Humacyte has developed a unique technology for growing human blood vessels for use in surgery. Its stock price is a bet that its bioengineered vessels will become a universal alternative for patients in need of vascular transplants.
Share prices of companies in the market segment - Reproduction
Humacyte (HUMA) is a biotechnology company developing versatile, bioengineered human tissues, specifically blood vessels, for use in vascular surgery and traumatology. We classify it as a "Reproduction" company. The chart below shows the dynamics in the cutting-edge regenerative medicine sector.
Broad Market Index - GURU.Markets
Humacyte is a regenerative medicine company that has developed a technology for growing bioengineered human blood vessels. Its breakthrough technology makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Humacyte compares to it.
Change in the price of a company, segment, and market as a whole per day
HUMA - Daily change in the company's share price Humacyte Inc.
The volatility of Humacyte, a tissue bioengineering company, reflects the risks and promises of regenerative medicine. Change_co measures the sensitivity to the results of clinical trials of its artificial blood vessels. This parameter is important for the formulas on System.GURU.Markets, which analyze high-risk biotech companies.
Daily change in the price of a set of shares in a market segment - Reproduction
Humacyte, Inc. is a biotech company. This chart demonstrates the sector's extreme volatility. Comparison with HUMA, which develops artificial blood vessels, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Humacyte is a biopharmaceutical company developing universal, artificially grown blood vessels. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Humacyte's technology.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Humacyte Inc.
For Humacyte, Inc., the year-to-date performance is a story about the creation of bioengineered human tissues. Its 12-month market cap depends entirely on progress toward FDA approval for its artificial blood vessels, which could revolutionize vascular surgery and dialysis by eliminating the need for a patient's own blood vessels.
Annual dynamics of market capitalization of the market segment - Reproduction
Humacyte, Inc. develops a unique technology for growing human tissue for use in vascular surgery. Its stock price is extremely volatile, reflecting investor confidence in its breakthrough potential and ability to commercialize its unique regenerative platform.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Humacyte, with its blood vessel-growing technology, is one of the most futuristic stories in medicine. Its stock price is completely unrelated to the economy. Its price reflects investors' faith in its revolutionary technology becoming a reality, and the price of that faith is extremely volatile.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Humacyte Inc.
The performance of Humacyte, a regenerative medicine company, is speculative. Monthly fluctuations on the chart do not reflect revenue, but rather news about the progress of clinical trials and regulatory approvals for its unique bioengineered blood vessels.
Monthly dynamics of market capitalization of the market segment - Reproduction
Humacyte is a company that uses biotechnology to grow human tissue and organs outside the body for subsequent implantation. Its primary goal is to create universal blood vessels. The chart below illustrates the general sentiment in the regenerative medicine sector, which promises to transform healthcare.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Humacyte, Inc. develops universal, artificially grown blood vessels. This is a revolutionary technology with enormous potential. The company's shares are driven by news of clinical trials and regulatory approvals. Their performance is completely uncorrelated with the market and is a bet on a medical breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Humacyte Inc.
Shares of Humacyte, a company that grows human tissue for medical applications, reflect expectations in regenerative medicine. Weekly price movements are highly volatile and depend on news about clinical trials and regulatory approvals of their bioengineered vessels. The chart below shows how short-term scientific developments influence the company's valuation.
Weekly dynamics of market capitalization of the market segment - Reproduction
How does Humacyte's performance compare to the broader biotech sector? This chart compares the tissue-engineering company's weekly stock price movements to the overall trend. This helps us understand whether its move, driven by news about bioengineered blood vessels, is a unique development on the cutting edge of science or a reflection of broader sentiment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Humacyte is developing a technology to grow human tissue for surgical applications. This breakthrough technology is not yet commercialized. This chart compares its weekly price action to the market, showing how its stock moves based on news about clinical trials and FDA decisions.
Market capitalization of the company, segment and market as a whole
HUMA - Market capitalization of the company Humacyte Inc.
Humacyte, Inc.'s market capitalization is a bet on its revolutionary technology for growing human blood vessels in the lab. The company's valuation at the commercialization stage depends on regulatory approval and acceptance by surgeons. The chart shows how investors assess the potential of this breakthrough in regenerative medicine.
HUMA - Share of the company's market capitalization Humacyte Inc. within the market segment - Reproduction
Humacyte, Inc. is seeking market share by developing versatile, bioengineered blood vessels of human origin. Its capitalization is a bet that its technology will revolutionize vascular surgery and dialysis.
Market capitalization of the market segment - Reproduction
This chart shows the overall market capitalization of the nascent regenerative medicine industry. Humacyte, with its technology for growing human blood vessels, is one of the pioneers. The chart's dynamics reflect investors' belief that bioengineering can solve the shortage of donor organs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart depicts the market value of a breakthrough biotechnology company. Humacyte's market capitalization is the valuation of its unique platform for growing human tissue, specifically blood vessels. The line illustrates how regenerative medicine can create enormous value and capture a share of the future of healthcare.
Book value capitalization of the company, segment and market as a whole
HUMA - Book value capitalization of the company Humacyte Inc.
This chart illustrates the scientific and manufacturing foundation of Humacyte, Inc. Its assets include patents and unique bioreactors for growing human acellular vessels (HAV). The chart's progress shows how the company is investing in the development and commercialization of this breakthrough regenerative technology.
HUMA - Share of the company's book capitalization Humacyte Inc. within the market segment - Reproduction
Humacyte's core assets are its unique bioreactors and production facilities for growing human tissue and blood vessels from cells. The chart shows the company's share of this revolutionary regenerative infrastructure, which could change the future of surgery and medicine.
Market segment balance sheet capitalization - Reproduction
Below you can see the overall book value of the biotech sector. Against this backdrop, Humacyte, which grows human tissue for medical purposes, is uniquely capital-intensive. Its business requires the ownership of highly sophisticated and sterile bioreactors, which poses a high technological and capital barrier.
Book value of all companies included in the broad market index - GURU.Markets
Humacyte is a unique company that grows bioengineered human blood vessels for surgical use. Its assets are not donor organs, but bioreactors and manufacturing facilities. Their balance sheet represents the value of a "factory" for creating universal "spare parts" for the human body.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Humacyte Inc.
Humacyte's balance sheet is the value of its bioreactors, where the vessels are grown. Its market capitalization represents a huge bet on its human "spare parts" technology being approved and commercially successful. The MvsBCap_Co chart shows how much the "dream" of regenerative medicine is worth compared to its current assets.
Market to book capitalization ratio in a market segment - Reproduction
Humacyte develops bioengineered human tissues for regenerative medicine, specifically blood vessels. Its value lies in its unique and potentially revolutionary platform. The chart shows the market's high valuation of its scientific potential, not its current tangible assets.
Market to book capitalization ratio for the market as a whole
Humacyte is a company that has developed a technology for growing bioengineered human blood vessels for use in surgery. This is a potentially revolutionary product for vascular surgery and dialysis. The company's value lies in its unique technology. This chart demonstrates why biotech companies can enjoy high valuations long before they reach profitability.
Debts of the company, segment and market as a whole
HUMA - Company debts Humacyte Inc.
For Humacyte, a biotech company developing artificial blood vessels, debt is a source of funding for innovation. This chart shows how the company raises capital to conduct final-stage clinical trials and prepare for commercial launch. In regenerative medicine, debt is the bridge between the lab and the operating room.
Market segment debts - Reproduction
Humacyte is developing a human tissue bioengineering technology to create universal blood vessels that can be implanted in any patient. This represents a breakthrough in regenerative medicine. This chart shows how the company is funding its unique and capital-intensive research, moving toward potential commercialization.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Humacyte Inc.
Humacyte develops bioengineered human tissues for use in vascular surgery. This chart shows the extent to which the company relies on debt to bring its unique technology to market. For a company at the intersection of biotech and medicine, debt poses a huge risk if the regulatory approval process is delayed.
Market segment debt to market segment book capitalization - Reproduction
Humacyte develops bioengineered human tissues for regenerative medicine, specifically blood vessels. This is a cutting-edge technology with a long development cycle. The chart shows how the company's debt load for funding clinical trials compares to the overall market capitalization of the biotech industry.
Debt to book value of all companies in the market
Humacyte (HUMA) develops universal, bioengineered human tissues that can be implanted into any patient. This is a breakthrough technology in regenerative medicine. This chart shows the overall market debt load. It illustrates why such innovative companies rely on equity capital to finance long R&D cycles.
P/E of the company, segment and market as a whole
P/E - Humacyte Inc.
This metric for Humacyte, Inc., a company that grows human tissue in the lab for use in vascular surgery, reflects its belief in regenerative medicine. There is no P/E ratio. The valuation is based on the potential of its technology to create universal blood vessels that are not rejected by the body.
P/E of the market segment - Reproduction
This is the average P/E for regenerative medicine companies. For Humacyte, which grows blood vessels, it serves as a benchmark. This metric reflects how highly investors, on average, value the potential of such breakthrough technologies, providing context for Humacyte's valuation as it moves toward commercialization.
P/E of the market as a whole
Humacyte develops and manufactures bioengineered human tissues for regenerative medicine. Its flagship product is a universal blood vessel that can be used in surgery without the risk of rejection. This risk appetite chart helps understand how investors evaluate breakthrough tissue engineering technologies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Humacyte Inc.
Humacyte is a bioengineering company that has developed a technology for creating universal, ready-to-use human blood vessels in the laboratory. This graph shows the expected revolution in vascular surgery. The estimate is contingent on regulatory approval and the commercial potential of its dialysis and trauma vessels.
%20P%2FE%20Humacyte%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Humacyte-Inc.&v=1772559045342 "Chart of the company's future (projected) P/E Humacyte Inc.")
Future (projected) P/E of the market segment - Reproduction
Humacyte develops and manufactures bioengineered human tissues for use in regenerative medicine, specifically blood vessels. This chart reflects the company's long-term profitability expectations. It shows whether the market believes their unique technology will be approved and widely used in surgery, becoming a new standard.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Reproduction&v=1772559045423 "Future (projected) P/E graph of the market segment - Reproduction")
Future (projected) P/E of the market as a whole
Humacyte is developing a technology for growing human tissue for use in vascular surgery. This is cutting-edge regenerative medicine. This market expectations chart is important because it reflects investors' risk appetite. Market optimism makes it easier for innovative companies like Humacyte to raise capital for long-term research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772559045492 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Humacyte Inc.
Humacyte is a regenerative medicine company. It has developed a technology for growing human blood vessels in the lab that can be implanted into patients without the risk of rejection. Its financial results reflect the costs of bringing this breakthrough technology to market.
Profit of companies in the market segment - Reproduction
Humacyte has developed a technology for growing human blood vessels for use in surgery. The company is on the verge of commercialization. This graph reflects the journey of regenerative medicine—from the laboratory to the patient. Current financial performance reflects an investment in a technology that has the potential to radically change surgical practice and the profitability of the sector.
Overall market profit
Humacyte develops and manufactures bioengineered human tissues for use in vascular surgery. This is a breakthrough in regenerative medicine. The company's success depends on regulatory approval and acceptance by surgeons, not on macroeconomic conditions. Its business is driven by innovation, not by the cycles depicted in this chart.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Humacyte Inc.
Humacyte is developing universal, bioengineered blood vessels that can be implanted in any patient without rejection. This graph shows revenue expectations, which are contingent on regulatory approval and successful commercialization of this breakthrough technology, which has the potential to transform vascular surgery.
%20profit%20of%20the%20company%20Humacyte%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Humacyte-Inc.&v=1772559045608 "Graph of future (projected) profit of the company Humacyte Inc.")
Future (predicted) profit of companies in the market segment - Reproduction
Humacyte develops and manufactures bioengineered human tissues for regenerative medicine applications, specifically blood vessels. This chart shows revenue projections for the reproductive medicine and regenerative technologies sector. It reflects expectations for the adoption of innovative tissue products, which is key to assessing the commercial potential of Humacyte's technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Reproduction&v=1772559045639 "Graph of future (predicted) profits of companies in a market segment - Reproduction")
Future (predicted) profit of the market as a whole
Humacyte develops human tissue bioengineering technology for use in vascular surgery. As a clinical-stage company, it relies on investor capital. The general economic forecasts presented here influence investor risk appetite and their willingness to fund breakthrough but not yet profitable medical technologies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772559045677 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Humacyte Inc.
Humacyte develops and manufactures universal, artificially grown blood vessels for use in surgery. This technology could eliminate the need for a patient's own blood vessels. This chart shows how investors assess the commercial potential of this breakthrough regenerative technology, which currently lacks stable revenue.
P/S market segment - Reproduction
Humacyte is a biotech company that develops and manufactures versatile, bioengineered human tissues that resist rejection. Its flagship product is artificial blood vessels for dialysis patients. This chart shows the average valuation in the sector, helping to understand the market premium for this potentially revolutionary regenerative technology.
P/S of the market as a whole
Humacyte is a regenerative medicine company that has developed a technology for growing human blood vessels outside the body, which can then be implanted into patients without the risk of rejection. This is a breakthrough technology. This chart compares the high revenue valuation of a high-tech biotech company with the more down-to-earth metrics of traditional companies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Humacyte Inc.
Humacyte develops bioengineered human tissues for regenerative medicine. Currently in the clinical stage, the company is valued based on its future prospects. This chart shows how investors view its revolutionary technology and its potential to create universal blood vessels and other tissues.
%20P%2FS%20Humacyte%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Humacyte-Inc.&v=1772559045728 "The graph of the company's future (projected) P/S Humacyte Inc.")
Future (projected) P/S of the market segment - Reproduction
Humacyte develops and manufactures bioengineered human tissues for use in regenerative medicine. This chart compares market expectations for its future revenue with other companies in the sector. The valuation reflects investors' faith in its breakthrough technology for creating ready-to-use blood vessels for surgery.
%20P%2FS%20market%20segment%20graph%20-%20Reproduction&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Reproduction&v=1772559045742 "Future (projected) P/S market segment graph - Reproduction")
Future (projected) P/S of the market as a whole
Humacyte is developing technology for growing human tissue and organs in the lab. This is the medicine of the future. The market optimism reflected in this chart is based on faith in breakthrough technologies. Humacyte needs this faith and significant capital to translate its revolutionary developments from the lab into clinical practice.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772559045772 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Humacyte Inc.
Humacyte is a bioengineering company developing versatile, artificially grown human tissues for medical applications, specifically blood vessels. Currently in late-stage clinical trials, its revenue comes from government contracts and grants. The chart below reflects the funding for this breakthrough regenerative technology.
Sales of companies in the market segment - Reproduction
Humacyte is a company that has developed a unique technology for growing bioengineered human tissue for use in vascular surgery. Its product, the human acellular vessel (HAV), can replace synthetic grafts and the patient's own vessels. This graph illustrates the potential of regenerative medicine, where Humacyte's innovations could radically change the standard of care.
Overall market sales
Humacyte is developing bioengineered human tissue technology for use in vascular surgery. This is a cutting-edge medical technology, the success of which depends on trial results and regulatory approval. The economic situation, as reflected here, impacts the availability of capital for R&D and the future solvency of the healthcare system.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Humacyte Inc.
Humacyte is a biotech company that grows bioengineered human blood vessels (HAVs) for use in vascular surgery. This could become an alternative to synthetic grafts. This timeline reflects analysts' expectations regarding FDA approval and the commercial potential of this breakthrough regenerative technology.
%20sales%20of%20the%20company%20Humacyte%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Humacyte-Inc.&v=1772559045889 "Schedule of future (projected) sales of the company Humacyte Inc.")
Future (projected) sales of companies in the market segment - Reproduction
Humacyte develops and manufactures bioengineered human tissues for use in regenerative medicine, specifically vascular prostheses. This chart reflects forecasts for the reproductive and regenerative medicine sector. Investors will want to assess whether the company's breakthrough technology can gain regulatory approval and change the standards of vascular surgery.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Reproduction&v=1772559045933 "Schedule of future (projected) sales of companies in the market segment - Reproduction")
Future (projected) sales of the market as a whole
Humacyte, Inc. develops universal, bioengineered human blood vessels for surgical use. This graph, reflecting investments in healthcare, is important to the company. Economic growth provides funding for medical innovation and hospitals' willingness to adopt advanced technologies, which determines Humacyte's future commercial success.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772559045937 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Humacyte Inc.
Humacyte develops and manufactures versatile, bioengineered human tissues for regenerative medicine. This breakthrough technology has the potential to replace synthetic implants and donor tissue. This chart illustrates the company's financial trajectory through clinical trials, showing the costs required to bring this innovation to market.
Market segment marginality - Reproduction
Humacyte, Inc. is a company that has developed technology for creating universal, bioengineered human blood vessels (HAVs). These vessels can be used in surgery without causing rejection. This chart reflects the scale of investment in this breakthrough regenerative technology, which is in late-stage clinical trials and has enormous market potential.
Market marginality as a whole
Humacyte has developed a technology for bioengineering human blood vessels that can be implanted in any patient. The overall profitability picture is irrelevant. This is a venture capital bet on revolutionizing vascular surgery. Success depends on regulatory approval and the ability to scale up production of these unique implants.
Employees in the company, segment and market as a whole
Number of employees in the company Humacyte Inc.
Humacyte—regenerative medicine in action, developing bioengineered blood vessels. This graph shows the team of scientists and manufacturing specialists. The growth of the staff reflects progress in clinical trials and preparations for commercial production of these unique human tissues.
Share of the company's employees Humacyte Inc. within the market segment - Reproduction
Humacyte develops and manufactures universal, bioengineered human tissues that can be implanted into any patient without rejection. This chart shows the percentage of specialists in the cutting-edge field of tissue engineering the company attracts. This reflects its unique technology and the team working to create "spare parts" for the human body.
Number of employees in the market segment - Reproduction
Humacyte develops and manufactures bioengineered human tissues for use in regenerative medicine, specifically blood vessels. This chart shows the growth of employment in this cutting-edge biotechnology field. The increase in the number of specialists reflects progress toward commercializing this unique platform, which has the potential to save lives and limbs.
Number of employees in the market as a whole
Humacyte, Inc. has developed a unique technology for growing human blood vessels in the laboratory for use in surgery. This is a breakthrough in regenerative medicine. This graph reflects the overall employment picture, and companies like Humacyte represent the future of healthcare, creating demand for specialists in biotechnology and tissue engineering.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Humacyte Inc. (HUMA)
Humacyte, Inc. develops bioengineered human tissues for regenerative medicine. It's a cutting-edge, science-intensive business. This chart shows an extremely high market capitalization per employee, as the company's value is determined not by its current assets, but by the potential of its revolutionary platform. A small team of scientists is creating technology that has the potential to transform medicine.
%20of%20the%20company%20Humacyte%20Inc.%20(HUMA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Humacyte-Inc.-HUMA&v=1772559046194 "Chart of market capitalization per employee (in thousands of dollars) of the company Humacyte Inc. (HUMA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Reproduction
Humacyte is developing a technology for creating bioengineered human tissue for regenerative medicine. This is a true scientific breakthrough. The chart shows the enormous future value the market is pricing in for this unique technology. The high per-employee value reflects investors' belief that a small team of scientists can change the future of surgery.
%20by%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Reproduction&v=1772559046213 "Market capitalization per employee (in thousands of dollars) by market segment - Reproduction")
Market capitalization per employee (in thousands of dollars) for the overall market
Humacyte is a regenerative medicine company that has developed a technology for creating universal, bioengineered blood vessels. This chart demonstrates the company's high market value per employee, highlighting the enormous potential of their platform for vascular surgery and dialysis.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772559046247 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Humacyte Inc. (HUMA)
Humacyte (HUMA) is a biotech company that grows human blood vessels (HAVs) in the lab for use in surgery. This is regenerative medicine. This chart shows the R&D expenses (negative profit) per employee. This represents an investment in technology that could revolutionize vascular surgery.
%20Chart%20Humacyte%20Inc.%20(HUMA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Humacyte-Inc.-HUMA&v=1772559046262 "Company Profit Per Employee (in thousands of dollars) Chart Humacyte Inc. (HUMA)")
Profit per employee (in thousands of dollars) in the market segment - Reproduction
Humacyte develops and manufactures bioengineered human tissues "off the shelf." Their first product is a blood vessel (HAV) for dialysis and surgery. This graph shows the benchmark performance of their biotech workforce and is important for assessing how well Humacyte is progressing toward commercializing this breakthrough technology.
%20in%20the%20market%20segment%20-%20Reproduction&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Reproduction&v=1772559046280 "Chart of profit per employee (in thousands of dollars) in the market segment - Reproduction")
Profit per employee (in thousands of dollars) for the market as a whole
Humacyte is a regenerative medicine company. They have learned to grow bioengineered human blood vessels (HAVs) in the lab for implantation. This requires highly complex manufacturing and R&D. This graph shows the high cost (negative profit) per employee involved in this futuristic process of creating "spare parts" for the human body.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772559046294 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Humacyte Inc. (HUMA)
Humacyte is a company engaged in bioengineering and growing human tissue for medical applications, specifically blood vessels. This chart reflects its status as an R&D company. No commercial revenue per employee is the norm for a company whose revolutionary technology is still undergoing clinical trials.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Humacyte-Inc.-HUMA&v=1772559046311 "Sales chart per company employee Humacyte Inc. (HUMA)")
Sales per employee in the market segment - Reproduction
Humacyte (HUMA) is a biotech company developing versatile, bioengineered human tissues (vessels) for regenerative medicine (e.g., dialysis or trauma). This chart shows how much revenue (from partnerships) each employee generates. It's an indicator of the productivity of their unique R&D platform.
Sales per employee for the market as a whole
Humacyte, Inc. is a regenerative medicine company. They grow "universal" human blood vessels (HAVs) in the lab. This breakthrough technology is in late-stage trials. This graph (near zero) shows their pre-commercialization status. Investors expect their unique manufacturing process to generate significant revenue once approved.
Short shares by company, segment and market as a whole
Shares shorted by company Humacyte Inc. (HUMA)
Humacyte, Inc. is a biotech company growing "universal" human blood vessels (HAVs) in the lab for transplantation. This chart shows bearish bets. The shorts are driven by high risks: the technology is highly complex, and the company is burning cash awaiting FDA approval and the commercial launch of its unique product.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Humacyte-Inc.-HUMA&v=1772559046361 "Short Shares Chart for the Company Humacyte Inc. (HUMA)")
Shares shorted by market segment - Reproduction
Humacyte (HUMA) is a biotech company that grows bioengineered human blood vessels (HAVs) in the lab for surgical use. This chart shows the bets against the entire MedTech sector. The rising bets against the industry reflect investor skepticism about the commercialization of this revolutionary but complex technology and FDA approval.
Shares shorted by the overall market
Humacyte (HUMA) develops bioengineered human tissue for vascular surgery. This technology is revolutionary, but far from profitable. This market pessimism chart shows "risk appetite." When investors are fearful, they are reluctant to fund scientific projects, and HUMA shares come under intense pressure.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Humacyte Inc. (HUMA)
Humacyte is a unique biotech company. They grow "bioengineered" human blood vessels (HAVs) in the lab for surgical applications. This is a breakthrough technology. This chart measures the level of hype. It shows when data euphoria (overbought) or doubts about the technology (oversold) reach a peak.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Humacyte-Inc.-HUMA&v=1772559046456 "RSI 14 indicator chart for the company's stock Humacyte Inc. (HUMA)")
RSI 14 Market Segment - Reproduction
Humacyte is a biotech company that grows bioengineered human blood vessels (HAVs) for use in vascular surgery and dialysis. This chart measures the overall momentum in the regenerative medicine sector. It helps determine whether the entire speculative segment is overheated by expectations.
RSI 14 for the overall market
Humacyte, a biotech company, depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like HUMA are forced to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast HUMA (Humacyte Inc.)
Humacyte is a biotech company developing bioengineered blood vessels (Human Acellular Vessels) for patients requiring vascular surgery. This chart shows the average target price. Analysts' forecasts are based on the potential for approval of this revolutionary technology and its applications in trauma and dialysis.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-HUMA-Humacyte-Inc.&v=1772559046551 "A chart showing analyst consensus forecasts for the expected stock price. HUMA (Humacyte Inc.)")
The difference between the consensus estimate and the actual stock price HUMA (Humacyte Inc.)
Humacyte (HUMA) is a biotech company developing bioengineered human blood vessels (HAVs), which could become a universal replacement for injuries or dialysis. This chart is a barometer of their R&D. It measures the gap between the price and the consensus target, reflecting the enormous potential analysts see in their regenerative technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-HUMA-Humacyte-Inc.&v=1772559046599 "A chart showing the difference between the consensus forecast and the actual stock price. HUMA (Humacyte Inc.)")
Analyst consensus forecast for stock prices by market segment - Reproduction
Humacyte (HUMA) is a regenerative medicine company that grows "universal" human blood vessels (HAVs) in bioreactors for surgery and dialysis. This chart shows general expectations for the regenerative medicine (and biotech) sector. It reflects whether experts believe in the future of "cultured" organs and tissues.
Analysts' consensus forecast for the overall market share price
Humacyte is a biotech company that has developed a unique technology for "bioengineered" blood vessels (HAVs), which are grown in the lab and are not rejected by the body. This chart shows the overall "risk appetite." For Humacyte, a company with a revolutionary surgical product, overall market optimism (a rising chart) is critical to funding the approval and commercialization process.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Humacyte Inc.
Humacyte (HUMA) is a regenerative medicine company. They're achieving the impossible: using bioreactors, they're growing universal (cell-free) human blood vessels (HAVs) that can be implanted into any patient without rejection. This chart is a clear indicator of faith in their futuristic R&D. It reflects their progress toward FDA approval and their enormous commercial potential.
AKIMA Market Segment Index - Reproduction
Humacyte is a pioneer in regenerative medicine, developing bioengineered blood vessels (HAVs) that could become a universal replacement for patients. This chart shows the average index for the biotech sector. It allows one to assess how Humacyte's breakthrough technology compares to the industry average based on the combined factors included in the index.
The AKIM Index for the overall market
Humacyte is a biotech company creating versatile human-derived tissues (HAVs) for vascular surgery and trauma. This chart, which reflects the market average, provides context. It helps assess how this innovative regenerative technology, ready for commercialization, compares to overall macroeconomic trends.
